S 38093
Alternative Names: S38093Latest Information Update: 27 Aug 2019
Price :
$50 *
At a glance
- Originator Servier
- Class Antidementias
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 27 Aug 2019 Discontinued - Phase-II for Alzheimer's disease (Combination therapy, In the elderly, In adults) in Austria, Finland, Spain, Sweden, Slovakia, Italy, Poland, United Kingdom, Germany, Portugal (PO)
- 27 Aug 2019 Discontinued - Phase-II for Alzheimer's disease in United Kingdom, Germany, Czech Republic, Portugal, Hungary, Bulgaria, Australia, Brazil, Chile, France, Mexico, Romania, Russia, South Africa, Austria (PO)
- 23 Jul 2015 Phase-II development is ongoing in the United Kingdom